title: Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
authors.affiliation: Center for Drug Evaluation and Research, FDA, Rockville, Maryland 20857.
authors.forename: C C
authors.initials: CC
authors.lastname: Peck
authors.forename: W H
authors.initials: WH
authors.lastname: Barr
authors.forename: L Z
authors.initials: LZ
authors.lastname: Benet
authors.forename: J
authors.initials: J
authors.lastname: Collins
authors.forename: R E
authors.initials: RE
authors.lastname: Desjardins
authors.forename: D E
authors.initials: DE
authors.lastname: Furst
authors.forename: J G
authors.initials: JG
authors.lastname: Harter
authors.forename: G
authors.initials: G
authors.lastname: Levy
authors.forename: T
authors.initials: T
authors.lastname: Ludden
authors.forename: J H
authors.initials: JH
authors.lastname: Rodman
mesh_terms: D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical; D004348:Drug Labeling; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology / Q000633:toxicity; D006801:Humans
chemical_list: D015507:Drugs, Investigational